Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Luxturna Market Size And Revenue Outlook Through 2030
The growth observed during the historic period was a result of the restricted availability of treatments for inherited retinal diseases, developments in viral vector technology, swift regulatory approvals for gene therapies, an increase in rare disease research funding, and the expanding adoption of genetic diagnostics.
The projected growth throughout the forecast period stems from the expansion of gene therapy pipelines, increased funding for treatments of rare diseases, wider implementation of early genetic screening, a greater emphasis on achieving long-term treatment results, and advancements in technologies for retinal drug delivery.
Key developments anticipated for the forecast period include a growing acceptance of gene therapy treatments, an intensifying focus on rare genetic eye conditions, increasing financial backing for one-time curative therapies, the proliferation of precision ophthalmology solutions, and improved integration between genetic screening and diagnostic processes.
Get A Free Sample Report With In-Depth Market Insights:
Luxturna Market Growth Catalysts And Demand Drivers
The luxturna market is expected to expand as the prevalence of genetic eye disorders increases. Genetic eye disorders encompass various inherited conditions stemming from gene mutations that disrupt the eyes’ structure or functionality, leading to visual impairments like blindness or reduced sight. This growing prevalence can be attributed to a rise in genetic mutations, aging demographics, advancements in diagnostic technologies, and heightened awareness of hereditary conditions. Luxturna is a gene therapy designed to treat specific inherited retinal diseases (IRDs) caused by mutations in the RPE65 gene, offering a potential remedy by delivering a functional gene copy to restore vision. For example, in December 2023, the United Nations Development Programme (UNDP), a US-based government agency, reported that 19,551 individuals were diagnosed with vision impairments in 2022. Moreover, over 19,000 new diagnoses were recorded in just the initial seven months of 2023. Thus, the increasing occurrence of genetic eye disorders is a significant factor boosting the luxturna market.
Luxturna Market Segments: Where Is Growth Concentrated?
The luxturna market covered in this report is segmented –
1) By Indication: Treatment Of RPE65-Mediated Inherited Retinal Disease, Management Of Vision Loss
2) By Patient Demographics: Pediatric Patients, Adult Patients, Patients With Early Diagnosis
3) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
4) By End User: Hospitals, Ophthalmology Clinics, Specialty Pharmacies, Research Institutions
Luxturna Market Trends Shaping Long-Term Demand
A significant development within the luxturna market involves conducting real-world studies for its gene therapies, particularly adeno-associated virus vector-based gene therapy, aiming to build a reputation for openness and dedication to patient results. Adeno-associated virus (AAV) vector-based gene therapy operates by employing a modified virus to introduce therapeutic genes into cells, thus providing a treatment option for genetic conditions such as RPE65-related retinal dystrophy. Illustratively, in April 2023, Spark Therapeutics, a US-headquartered biotechnology firm focused on gene therapy treatments, presented real-world findings for Luxturna (voretigene neparvovec), an AAV-based gene therapy for RPE65-related inherited retinal dystrophy (IRD), derived from 8 Belgian patients, at the ARVO 2023 Annual Meeting. Within the observational study, involving 15 treated eyes, notable enhancements in light sensitivity were recorded 6 months following treatment for red, blue, and white light, alongside improvements in the visual field (object III4). After 2 years post-treatment, Luxturna demonstrated an average change of -0.03 BCVA and -13.67 decibels concerning the full-field light sensitivity threshold. Pertaining to safety, 35% of patients encountered a minimum of one ocular adverse event, the most prevalent being chorioretinal atrophic changes, documented in 13 cases.
Luxturna Market Key Participants And Competitive Landscape
Major companies operating in the luxturna market are F. Hoffmann-La Roche AG
View The Full Luxturna Market Report:
Luxturna Market Regional Analysis And Leading Geography
North America was the largest region in the luxturna market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the luxturna market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
